Literature DB >> 26954701

Loss of FBXW7 is related to the susceptibility and poor prognosis of cervical squamous carcinoma.

Ye Xu1, Jiawei Yu2, Tianbo Liu1, Fanling Meng1, Dan Kong1, Ge Lou1.   

Abstract

OBJECTIVE: To investigate the relationship between F box/WD-40 domain protein 7 (FBXW7) and cervical squamous cancer.
METHODS: We investigated the FBXW7 expression in 136 cervical squamous carcinoma cases through immunohistochemistry and Western-blot analysis to evaluate the clinical significance of FBXW7 and to elucidate the relationship of FBXW7 expression with progression-free survival (PFS) and overall survival (OS).
RESULTS: Low FBXW7 expression was associated with high histologic grade, lymphovascular space invasion and lymph node metastasis, among other parameters. Patients with low FBXW7 expression exhibited poor OS and PFS.
CONCLUSIONS: FBXW7 is related to the susceptibility and prognosis of cervical squamous carcinoma, indicating FBXW7 may be a potentially important target for the prediction of prognosis.

Entities:  

Keywords:  Biomarker; lymph node metastasis; suppressor gene

Mesh:

Substances:

Year:  2016        PMID: 26954701     DOI: 10.3109/1354750X.2016.1148778

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  3 in total

1.  Lipid metabolism regulator human hydroxysteroid dehydrogenase-like 2 (HSDL2) modulates cervical cancer cell proliferation and metastasis.

Authors:  Yang Yang; Anna Han; Xinyue Wang; Xianglin Yin; Minghua Cui; Zhenhua Lin
Journal:  J Cell Mol Med       Date:  2021-03-18       Impact factor: 5.310

2.  Gfi-1 promotes proliferation of human cervical carcinoma via targeting of FBW7 ubiquitin ligase expression.

Authors:  Hongbing Cai; Fan Zhang; Zhen Li
Journal:  Cancer Manag Res       Date:  2018-08-23       Impact factor: 3.989

Review 3.  Prognostic values of F-box members in breast cancer: an online database analysis and literature review.

Authors:  Xiaochen Wang; Tao Zhang; Shizhen Zhang; Jinlan Shan
Journal:  Biosci Rep       Date:  2019-01-03       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.